ARTICLE SUMMARY:
After struggling for years to gain traction, the US continuous glucose monitoring market has finally found its footing. Now growing at double digits, CGM adoption is being driven by more accurate, patient-friendly devices; vastly improved payor coverage; and recently launched direct-to-consumer marketing campaigns. Although DexCom, Abbott, and Medtronic dominate the space, Senseonics has what could be a game-changer for some patients.
As the diabetes device market continues its relentless march toward a more connected, intelligent, and patient-friendly future, novel disease management solutions are being added to the mix at a swift pace.
